Content area

|
|

Immuncheckpointantistoffer øger overlevelsen for patienter med metastatisk melanom

Kutant melanom. (Foto: Pia Sjøgren).
Forfatter(e)
Louise Elkjær Fløe1, Inge Marie Svane2, Lars Bastholt3 & Henrik Schmidt1 1) Onkologisk Afdeling, Aarhus Universitetshospital 2) Center for Cancer Immunterapi, Herlev Hospital 3) Onkologisk Afdeling, Odense Universitetshospital Ugeskr Læger 2016;178:V01160070
Reference: 
Ugeskr Læger 2016;178:V01160070
Blad nummer: 
Sidetal: 
2-5
Immune checkpoint antibodies increase survival in patients with metastatic melanoma
The incidence of melanoma is rising and until recently, metastatic melanoma had a poor survival prognosis. Manipulation of two newly discovered immune pathways have shown impressive results. The first is treatment with anti-cytotoxic T-lymphocyte-antigen (CTLA)-4 antibody which blocks the inhibitory receptor CTLA-4. The other is anti-programmed cell death (PD)-1 antibody which blocks the inhibitory receptor PD-1 on T-cells. Thereby, the T-cells are kept activated and able to attack cancer cells.
Du skal være logget ind for at læse denne artikel
Log ind

Right side

af Lise Kay | 05/04
2 kommentarer
af Mads Wissenberg Jørgensen | 04/04
2 kommentarer
af Morten Krause Nielsen | 03/04
1 Kommentar
af Knud Gade Freund | 01/04
2 kommentarer
af Knud Erik Alsbirk | 30/03
1 Kommentar
af Andreas Schröder | 29/03
1 Kommentar
af Steen Frobenius | 29/03
4 kommentarer